Yin-Cheong Wong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6500063/publications.pdf

Version: 2024-02-01

26 papers	858 citations	586496 16 h-index	620720 26 g-index
27 all docs	27 docs citations	27 times ranked	1434 citing authors

#	Article	IF	Citations
1	Utility of Animal Models to Understand Human Alzheimerâ€™s Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. International Journal of Molecular Sciences, 2020, 21, 3158.	1.8	12
2	Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human. Journal of Clinical Pharmacology, 2019, 59, 731-747.	1.0	9
3	Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat. European Journal of Pharmaceutical Sciences, 2018, 111, 514-525.	1.9	6
4	Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. European Journal of Pharmaceutical Sciences, 2018, 112, 168-179.	1.9	59
5	Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. Life Sciences, 2018, 207, 428-435.	2.0	18
6	Fingerprints of <scp>CNS</scp> drug effects: a plasma neuroendocrine reflection of <scp>D</scp>₂ receptor activation using multiâ€biomarker pharmacokinetic/pharmacodynamic modelling. British Journal of Pharmacology, 2018, 175, 3832-3843.	2.7	7
7	Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. Drug Discovery Today, 2017, 22, 896-911.	3.2	165
8	Brain Uptake of Bioactive Flavones in Scutellariae Radix and Its Relationship to Anxiolytic Effect in Mice. Molecular Pharmaceutics, 2017, 14, 2908-2916.	2.3	25
9	Predicting Drug Concentrationâ€Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologicallyâ€Based Pharmacokinetic Model. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 765-777.	1.3	61
10	Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics. Expert Opinion on Drug Discovery, 2017, 12, 1207-1218.	2.5	35
11	A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations. Pharmaceutical Research, 2017, 34, 333-351.	1.7	59
12	Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling. AAPS Journal, 2017, 19, 274-285.	2.2	10
13	Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients. Expert Opinion on Drug Discovery, 2016, 11, 45-63.	2.5	27
14	Identification and disposition of novel monoâ€hydroxyl mefenamic acid and their potentially toxic 1â€Oâ€acylâ€glucuronides in vivo. Biopharmaceutics and Drug Disposition, 2015, 36, 529-551.	1.1	2
15	Herbâ€“drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats. Journal of Ethnopharmacology, 2015, 170, 106-116.	2.0	32
16	Alterations in the CNS effects of anti-epileptic drugs by Chinese herbal medicines. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 249-267.	1.5	12
17	Development of a SPE-LC/MS/MS method for simultaneous quantification of baicalein, wogonin, oroxylin A and their glucuronides baicalin, wogonoside and oroxyloside in rats and its application to brain uptake and plasma pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2014, 97, 9-23.	1.4	57
18	Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. International Journal of Pharmaceutics, 2014, 468, 272-282.	2.6	94

#	Article	IF	Citations
19	Pharmacokinetic Comparison Between the Long-Term Anesthetized, Short-Term Anesthetized and Conscious Rat Models in Nasal Drug Delivery. Pharmaceutical Research, 2014, 31, 2107-2123.	1.7	9
20	Brain Disposition and Catalepsy After Intranasal Delivery of Loxapine: Role of Metabolism in PK/PD of Intranasal CNS Drugs. Pharmaceutical Research, 2013, 30, 2368-2384.	1.7	22
21	Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 833-854.	1.5	12
22	Comment on Uridine Diphosphate Glucuronosyltransferase Isoform-Dependent Regiospecificity of Glucuronidation of Flavonoids: Applicability of UV Spectrum Shifts in Identification of Glucuronidation Position in Flavones and Flavonols. Journal of Agricultural and Food Chemistry, 2012, 60, 4416-4419.	2.4	1
23	Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2012, 58, 83-93.	1.4	25
24	Intranasal Deliveryâ€”Modification of Drug Metabolism and Brain Disposition. Pharmaceutical Research, 2010, 27, 1208-1223.	1.7	42
25	Intestinal first-pass glucuronidation activities of selected dihydroxyflavones. International Journal of Pharmaceutics, 2009, 366, 14-20.	2.6	24
26	Structureâ€“activity relationships of the glucuronidation of flavonoids by human glucuronosyltransferases. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1399-1419.	1.5	33